The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome

Published on 20/06/2024

The ALPESTRIA-1 Phase 2 clinical study (NCT06425055) is an open-label, single arm, fixed dose escalation of the investigational drug Vonafexor. This study is a proof-of-concept trial of Vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome. The study aims to recruit 20 patients in the US and EU (France, Spain and Germany).

The first site for patient recruitment is now open in Idaho (US) and more sites will open in the coming weeks.

More information about the study here:

Read next in 'Latest news'

• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
• Swiss NASH Foundation sponsorship